Vol. 6 No. 10 (2026): October
Reimbursement Reviews

Tafasitamab (Minjuvi)

decorative image of the issue cover

Published October 5, 2026

Key Messages

  • Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses Tafasitamab (Minjuvi), 200 mg single-use vial (lyophilized powder for solution) for IV infusion.
  • Indication: Tafasitamab in combination with lenalidomide for the treatment of adult patients with R/R DLBCL not otherwise specified, including DLBCL arising from low grade lymphoma, who are not eligible for ASCT.